HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Kura Oncology and maintained a price target of $32.
October 24, 2024 | 10:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Kura Oncology, maintaining a price target of $32, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $32 price target by a reputable analyst suggests a positive outlook for Kura Oncology, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100